Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)

NCT05537766 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT05537766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05537766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)
Lead sponsor
Kite, A Gilead Company
Phase
Phase 2
Overall status
Terminated
Start date
November 1, 2022
Completion date
January 27, 2025
Enrollment
19 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory burkitt lymphoma, relapsed/refractory hairy cell leukemia, relapsed/refractory richter transformation, relapsed/refractory waldenstrom macroglobulinemia